Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray to Help in Combating SARS-CoV-2
Today, Xlear is filing a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA). The Pre-EUA is a first step in seeking authorization of Xlear Nasal Spray as a new hygiene tool to help in combat the SARS-CoV-2 virus, the virus that causes COVID-19.
Xlear’s Pre-EUA Request is based on initial data suggesting Xlear Nasal Spray may reduce SARS-CoV-2 viral load in the nose, and otherwise attenuate the virus. “Studies show that regular nasal cleansing may help reduce viral infections, including from the SARS-CoV-2 virus (COVID-19),” said Dr. Gustavo Ferrer, a doctor and global respiratory disease expert who has studied the use of Xlear Nasal Spray to combat SARS-CoV-2. “The concept is straight-forward: Cleansing the nose means less virus, less virus produces less risk of infection,” Dr. Ferrer added.
The Pre-EUA Request is focused on the cleansing uses of Xlear, however it follows on recent studies suggesting Xlear is both antiviral and virucidal against SARS-CoV-2:
- A clinical case study of three “[s]ymptomatic, COVID-19 patients, treated with [Xlear],” found “rapid clinical improvement and shorten[ed] time” to negative PCR tests. https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extract-nasal-spray-solution-in-covid-19-case-series .
- Xylitol, which is one of the Ingredients of Xlear, has been shown to have inhibitory properties versus SARS-CoV-2 in cell culture, in vitro . https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1.full
- Later in vitro studies with Xlear suggested it might provide a “replicable means to deactivate SARS-CoV-2 . . . to an undetectable amount of infectious virus.” https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
The linchpin of FDA’s COVID-19 EUA determinations is a risk-benefit assessment — given the threat of a global pandemic, do the possible benefits of the emergency use, outweigh any known risks. Xlear has been used by millions of people over the last twenty years for cleansing and moisturizing the nasal cavities without a single report of a significant adverse event. At the same time, preliminary data shows Xlear has potential benefits versus SARS-CoV-2. “More research will be needed to confirm the effectiveness of Xlear versus SARS-CoV-2. However, we believe the available data clearly shows potential benefits outweigh any practically non-existent risks, ” said Nate Jones, CEO of Xlear. “We hope to move forward quickly with FDA to address a gap in current hygiene strategies against SARS-CoV-2. People should be using Xlear as part of a layered defense to prevent getting COVID-19. If everyone used Xlear, in addition to taking other steps recommended by public health officials, we believe we could drive SARS-CoV-2 infection rates down nationwide,” Jones added.
Xlear is currently sold in over 50,000 pharmacies, grocery stores, and online as a nasal irrigant for cleansing and moisturizing the nasal cavities.
More information on Xlear: https://xlear.com/
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PITNEY-BOWES-INC.19.1.2021 15:02:42 CET | Press release
Pitney Bowes Appoints Ana Maria Chadwick as Executive Vice President and Chief Financial Officer
CA-GLOBALITY19.1.2021 14:02:48 CET | Press release
Globality, the World’s First Smart Sourcing Platform Powered by AI, Raises $138.3 Million of Series E Funding From Sienna Capital, a Wholly Owned Subsidiary of Groupe Bruxelles Lambert, and the SoftBank Vision Fund
CA-ZYNGA19.1.2021 14:02:48 CET | Press release
Zynga Launches Harry Potter: Puzzles & Spells in South Korea
PPRO19.1.2021 14:02:48 CET | Press release
PPRO Raises $180 Million for the Next Era of Local Payments Infrastructure, Is Now Valued Over $1 Billion
ARTMS/ISOTOPIA19.1.2021 14:02:48 CET | Press release
ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 With Cyclotron Produced 68Ga Utilizing the QUANTM Irradiation System™ and Solid Targets
EVERBRIDGE19.1.2021 13:32:46 CET | Press release
Everbridge Unveils Next-Generation Front-End Alerting Interface for Industry-Leading Global Public Warning Platform
CO-HEMPFUSION19.1.2021 13:07:42 CET | Press release
HempFusion’s Wholly Owned Subsidiary Probulin Probiotics Launches Amazon Store and Expands Brick and Mortar Product Selection
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom